Liquidia Corporation (LQDA) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The upward trend in estimate revisions for this company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revis ...

Liquidia Corporation (LQDA) closed the last trading session at $36.86, gaining 8.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $49.89 indicates a 35.4% upside potential.The average comprises nine short-term price targets ranging from a low of $19.00 to a high of $67.00, with a standard deviation of $13.66. While the lowest estimate indicates a decline of 48.5% from the current ...

Industry Overview - The biotech industry has shown strong performance in 2026, driven by robust fourth-quarter results, new drug approvals, and progress in drug pipelines despite regulatory challenges and pricing pressures [1][12] - The sector is expected to continue attracting investor interest due to the ongoing demand for innovative medical treatments [1] Mergers and Acquisitions - A recent increase in M&A activity is supporting sector momentum, with large pharmaceutical and biotech companies expanding their portfolios through strategic collaborations and acquisitions [2][8] - Notable acquisitions include Johnson & Johnson's purchase of Halda Therapeutics for prostate cancer treatment and Novartis's acquisition of Avidity Biosciences for $12 billion to enhance its neuroscience pipeline [10][11] Company Performance - Biotech companies such as Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia Corporation are positioned to outperform the sector [3] - Liquidia Corporation's Yutrepia generated sales of $148.3 million in 2025, with a strong growth trajectory expected [24][25] - ANI Pharmaceuticals reported a 75.6% increase in sales of its ACTH-based injection Cortrophin Gel, reaching $347.8 million in 2025 [27][28] - ADMA Biologics is experiencing strong growth driven by Asceniv, with expectations for revenue acceleration in 2026 [31][32] - Terns Pharmaceuticals is advancing its lead candidate TERN-701, with promising data presented at a recent meeting [34][35] Industry Trends - The focus on innovation and execution is critical, with significant investments in drug development and the use of AI technology in drug discovery [5][12] - Successful commercialization remains a challenge for smaller biotech firms, often leading to collaborations with larger companies [6][7] Market Performance - The Zacks Biomedical and Genetics industry has outperformed both the Zacks Medical sector and the S&P 500, gaining 18.8% over the last six months compared to 5.6% and 3.3% respectively [18] - The industry is currently trading at a trailing 12-month price-to-sales ratio of 2.40X, lower than the S&P 500's 5.63X [21]

Core Insights - Liquidia Corp reported mixed results for Q4, with earnings of 15 cents per share, missing the analyst consensus estimate of 17 cents per share, while quarterly sales of $92.021 million exceeded the estimate of $83.634 million [1] Financial Performance - Quarterly earnings: 15 cents per share, below the consensus estimate of 17 cents per share [1] - Quarterly sales: $92.021 million, surpassing the consensus estimate of $83.634 million [1] Market Reaction - Following the earnings announcement, Liquidia shares increased by 4.5%, trading at $36.08 [2] Analyst Ratings and Price Targets - HC Wainwright & Co. analyst Andrew S. Fein maintained a Buy rating and raised the price target from $50 to $55 [4] - Wells Fargo analyst Benjamin Burnett maintained an Overweight rating and increased the price target from $31 to $44 [4] Product Adoption - CEO Dr. Roger Jeffs highlighted the rapid adoption of YUTREPIA® in clinical practice, noting it as one of the top specialty drug launches in the past five years across all therapeutic categories [2]

Core Insights - Liquidia has demonstrated strong growth in its product YUTREPIA, with significant market share gains and a rapid commercial ramp since its launch [3][5][12] Financial Performance - For FY2025, YUTREPIA net product sales reached $148.3 million, with Q4 sales of $90.1 million reflecting a 74% increase compared to Q3 [5][7] - The company achieved its second consecutive profitable quarter, reporting non-GAAP EBITDA of $27.3 million and net income of $14.6 million, ending the year with approximately $190.7 million in cash [8][5] Market Dynamics - Liquidia accounted for approximately 17% of market revenue in Q4, up from 10% in Q3, indicating a strong position in the inhaled treprostinil market [12][11] - The company has seen over 3,600 unique patient referrals and therapy shipped for more than 2,900 patients since launch, with around 860 prescribers [6][2] Clinical Expansion Plans - Liquidia plans to initiate multiple studies in 2026, including transition trials and new indications such as systemic sclerosis-associated Raynaud's phenomenon and PH-COPD [4][14] - The company aims to advance its next-generation candidate L-606 into pivotal studies, targeting a franchise worth at least $1 billion by 2027 [4][16] Competitive Landscape - Liquidia does not view the recently announced soft mist inhaler (SMI) as offering significant clinical advantages, maintaining that its formulation provides better tolerability and lower airway penetration [19][20] - The company anticipates that new oral outcomes data in the prostacyclin receptor agonist category will not significantly impact YUTREPIA's launch [20] Payer Access and Market Strategy - Liquidia has maintained over 85% "pull-through" from prescription to patient start since the launch, aiming to ensure patient access to YUTREPIA [22] - The company plans to expand its sales force by approximately 33% to enhance its market presence, particularly in the community setting for PH-ILD [13][4]

Core Viewpoint - Liquidia Corporation is positioned as a strong investment opportunity in the biopharmaceutical industry, particularly focusing on innovative inhaled therapies for rare cardiopulmonary diseases, with a significant emphasis on its lead product, YUTREPIA [1] Financial Performance - For Q4 2025, Liquidia reported earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.08, and marking a turnaround from a loss of approximately $0.46 per share in the same quarter the previous year [3] - The company achieved a net income of approximately $14.6 million and positive adjusted EBITDA for the quarter [3] - Revenue for Q4 reached $92.02 million, primarily driven by YUTREPIA net product sales of around $90.1 million, surpassing expectations by 19.34% [4] Product Launch and Market Impact - The successful commercial launch of YUTREPIA in June 2025 contributed to significant revenue growth, with full-year 2025 sales estimated at approximately $148.3 million and over 2,900 patients treated [4] - Liquidia has consistently outperformed revenue estimates in recent quarters, indicating strong market acceptance and demand for its products [4] Stock Performance and Market Position - Despite strong financial results, LQDA stock faced some pressure post-earnings, trading around $33–$34, with a yearly range from approximately $11.26 to $46.67 [5] - Liquidia's market capitalization is around $3 billion, with a robust cash position of approximately $190.7 million at year-end 2025, supporting ongoing investments in pipeline expansion [6] Analyst Ratings - Raymond James has reiterated a "Strong Buy" rating for Liquidia Corporation, with a recent price target set at $47, reflecting confidence in the company's growth potential [2][7]

Financial Data and Key Metrics Changes - For the full year 2025, YUTREPIA generated $148.3 million in net product sales, including $90.1 million in the fourth quarter, representing a 74% growth in net product sales over the third quarter 2025 [9] - The fourth quarter marked the second consecutive quarter of increasing profitability with a non-GAAP adjusted EBITDA of $27.3 million and a net income of $14.6 million [9] - The company ended the year with approximately $190.7 million in cash and cash equivalents, having generated $33 million of positive cash flow in the fourth quarter alone [10] Business Line Data and Key Metrics Changes - The company has received more than 3,600 unique patient referrals and shipped therapy for over 2,900 patients since the launch of YUTREPIA, maintaining a robust trajectory [4] - New patient prescriptions are roughly equal between PAH and PH-ILD indications, with patient starts remaining at 75% naive to 25% transitions from other prostacyclins [5][6] - The total number of prescribers has increased to around 860, with approximately 25% of physicians referring five or more patients [6] Market Data and Key Metrics Changes - Inhaled treprostinil revenue for Q4 was approximately $550 million, with the company accounting for more than 100% of market growth in Q4 [16] - The company's market share increased from about 10% in Q3 to 17% in Q4, indicating significant growth quarter-over-quarter [17] Company Strategy and Development Direction - The company aims to build a durable franchise with increasing patient preference and a clear path towards at least a billion-dollar franchise by 2027 [11] - The development strategy includes initiating multiple new studies to transition patients from oral and inhaled prostacyclin therapies and exploring additional disease areas such as systemic sclerosis-associated Raynaud's phenomenon and PH-COPD [7][8] - The company plans to enhance its sales force by a third to penetrate the PH-ILD market further [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of YUTREPIA, noting that the depth of prescriptions is increasing and that there are no anticipated impediments to growth [18] - The management team believes that the competitive landscape, including new oral therapies, will not significantly impact their business, as YUTREPIA offers a better benefit-to-risk profile [20][22] - The company is optimistic about its ability to continue capturing market share and achieving its revenue targets [41] Other Important Information - The company is currently involved in legal proceedings, with management expressing confidence in their position and the expected outcomes [46] - The payer access remains strong, with an 85% prescription to patient start conversion rate, and the company continues to work on improving access [48] Q&A Session Summary Question: Current market share and growth expectations for YUTREPIA - Management indicated that while precise market share is hard to determine, revenue analysis suggests significant growth, with a 17% market share in Q4 [15][16] Question: Impact of new competitor data on YUTREPIA - Management believes that new oral therapies will not significantly impact YUTREPIA's launch trajectory, as they do not provide the same symptomatic benefits [19][20] Question: Differentiation of YUTREPIA compared to competitors - Management highlighted that YUTREPIA's product profile is superior due to its ease of use, low resistance, and high portability, which are not matched by competitors [30][31] Question: Transition of patients from other therapies - Approximately 30% of patients transitioning to YUTREPIA in PAH are coming from oral therapies, with the remainder from inhaled therapies [78] Question: Updates on legal matters and payer access - Management provided updates on ongoing legal proceedings and expressed confidence in their position, while also noting strong payer access with an 85% pull-through rate [46][48]

Liquidia (NasdaqCM:LQDA) Q4 2025 Earnings call March 05, 2026 08:30 AM ET Speaker7Good morning, and welcome to the Liquidia Corporation Full Year 2025 Financial Results and Corporate Update Conference Call. My name is Josh and I will be your operator today. All participants are currently in listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions for joining the queue will be provided at that time. Please note that today's call is being recorded. I'll now tur ...

分组1 - Liquidia Corporation reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.08 per share, compared to a loss of $0.46 per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $92.02 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 19.34%, compared to year-ago revenues of $2.92 million [2] - Liquidia Corporation has surpassed consensus EPS estimates two times and revenue estimates three times over the last four quarters [2] 分组2 - The current consensus EPS estimate for the coming quarter is $0.20 on revenues of $79.43 million, and for the current fiscal year, it is $1.05 on revenues of $368.29 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 46% of over 250 Zacks industries, indicating that the industry outlook can materially impact stock performance [8]

©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 2 Full Year 2025 Earnings & Corporate Update Liquidia Corporation March 5, 2026 ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward-looking statements This presentation may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operations and financial position, o ...